Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

BACKGROUND: Pathological and genetic evidence implicates toxic effects of aggregated α‐synuclein in the pathophysiology of neuronal dysfunction and degeneration in Parkinson's disease. Immunotherapy targeting aggregated α‐synuclein is a promising strategy for delaying disease progression. OBJEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Brys, Miroslaw, Fanning, Laura, Hung, Serena, Ellenbogen, Aaron, Penner, Natalia, Yang, Minhua, Welch, Mackenzie, Koenig, Erica, David, Eric, Fox, Tara, Makh, Shavy, Aldred, Jason, Goodman, Ira, Pepinsky, Blake, Liu, YuTing, Graham, Danielle, Weihofen, Andreas, Cedarbaum, Jesse M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771554/
https://www.ncbi.nlm.nih.gov/pubmed/31211448
http://dx.doi.org/10.1002/mds.27738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771554/
https://www.ncbi.nlm.nih.gov/pubmed/31211448
http://dx.doi.org/10.1002/mds.27738

Ejemplares similares